HK1214129A1 - 用於綴合疫苗的經過修飾的多糖 - Google Patents
用於綴合疫苗的經過修飾的多糖Info
- Publication number
- HK1214129A1 HK1214129A1 HK16101987.5A HK16101987A HK1214129A1 HK 1214129 A1 HK1214129 A1 HK 1214129A1 HK 16101987 A HK16101987 A HK 16101987A HK 1214129 A1 HK1214129 A1 HK 1214129A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- conjugate vaccines
- modified polysaccharides
- polysaccharides
- modified
- vaccines
- Prior art date
Links
- 108010060123 Conjugate Vaccines Proteins 0.000 title 1
- 229940031670 conjugate vaccine Drugs 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 229920001282 polysaccharide Polymers 0.000 title 1
- 239000005017 polysaccharide Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94522607P | 2007-06-20 | 2007-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1214129A1 true HK1214129A1 (zh) | 2016-07-22 |
Family
ID=40156674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16101987.5A HK1214129A1 (zh) | 2007-06-20 | 2016-02-23 | 用於綴合疫苗的經過修飾的多糖 |
Country Status (9)
Country | Link |
---|---|
US (3) | US20100189740A1 (zh) |
EP (1) | EP2170391B1 (zh) |
JP (1) | JP5555623B2 (zh) |
CN (2) | CN105267974A (zh) |
AU (1) | AU2008265767B2 (zh) |
CA (1) | CA2692069C (zh) |
ES (1) | ES2621359T3 (zh) |
HK (1) | HK1214129A1 (zh) |
WO (1) | WO2008157590A1 (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
EP2411039A4 (en) * | 2009-03-23 | 2015-05-06 | Brigham & Womens Hospital | Glycoconjugate VACCINES |
WO2011040969A1 (en) * | 2009-09-30 | 2011-04-07 | Massachusetts Institute Of Technology | Compositions and methods for the treatment of atherosclerosis and other related diseases |
CN102002077B (zh) * | 2010-01-26 | 2014-08-27 | 深圳伯美生物医药有限公司 | 一种唾液酸-蛋氨酸锌新型偶联物、制备工艺及其应用 |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
CN101972475B (zh) * | 2010-04-12 | 2014-04-09 | 李建平 | 一种细菌多糖-蛋白结合疫苗及其制备方法 |
BR112013012626A2 (pt) * | 2010-12-10 | 2016-07-19 | Merck Sharp & Dohme | formulação, composição imunogênica, e, seringa pré-carregada |
IN2015DN00694A (zh) * | 2012-08-16 | 2015-06-26 | Pfizer | |
PL404229A1 (pl) * | 2013-06-06 | 2014-12-08 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie |
CN105934251A (zh) * | 2014-01-21 | 2016-09-07 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
WO2015110941A2 (en) * | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
PT3096786T (pt) * | 2014-01-21 | 2021-08-24 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
JP2017505792A (ja) | 2014-02-14 | 2017-02-23 | ファイザー・インク | 免疫原性糖タンパク質コンジュゲート |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
SG10202005253TA (en) * | 2015-07-21 | 2020-07-29 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
MX2019002489A (es) | 2016-09-02 | 2019-10-21 | Sanofi Pasteur Inc | Vacuna contra neisseria meningitidis. |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
KR102634811B1 (ko) * | 2017-06-10 | 2024-02-06 | 인벤트프라이즈 인크. | 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
CN109879967A (zh) * | 2017-12-15 | 2019-06-14 | 苏州和锐生物科技有限公司 | 一种乙酰氨基葡萄糖偶联物的制备方法及应用 |
CN108743936B (zh) * | 2018-06-14 | 2022-03-15 | 中国科学院过程工程研究所 | 一种细菌多糖结合疫苗及其制备方法与应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
AU641715B2 (en) * | 1989-12-14 | 1993-09-30 | National Research Council Of Canada | Improved meningococcal polysaccharide conjugate vaccine |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5425946A (en) * | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
ATE252602T1 (de) * | 1996-08-27 | 2003-11-15 | Chiron Corp | Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen |
FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
NZ509986A (en) * | 1998-08-19 | 2003-10-31 | Baxter Healthcare S | Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines |
WO2006002402A2 (en) * | 2004-06-23 | 2006-01-05 | Children's Hospital & Research Center At Oakland | Polysaccharide derivatives and uses in induction of an immune response |
WO2007125089A2 (en) * | 2006-04-28 | 2007-11-08 | ETH Zürich | Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections |
-
2008
- 2008-06-18 US US12/664,798 patent/US20100189740A1/en not_active Abandoned
- 2008-06-18 CN CN201510581713.6A patent/CN105267974A/zh active Pending
- 2008-06-18 AU AU2008265767A patent/AU2008265767B2/en not_active Ceased
- 2008-06-18 CN CN200880025103A patent/CN101754773A/zh active Pending
- 2008-06-18 WO PCT/US2008/067315 patent/WO2008157590A1/en active Application Filing
- 2008-06-18 JP JP2010513375A patent/JP5555623B2/ja active Active
- 2008-06-18 EP EP08771342.6A patent/EP2170391B1/en active Active
- 2008-06-18 ES ES08771342.6T patent/ES2621359T3/es active Active
- 2008-06-18 CA CA2692069A patent/CA2692069C/en active Active
-
2013
- 2013-01-02 US US13/732,861 patent/US20130197203A1/en not_active Abandoned
-
2016
- 2016-02-23 HK HK16101987.5A patent/HK1214129A1/zh unknown
- 2016-03-01 US US15/057,276 patent/US20160175430A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100189740A1 (en) | 2010-07-29 |
JP2010532793A (ja) | 2010-10-14 |
US20130197203A1 (en) | 2013-08-01 |
ES2621359T3 (es) | 2017-07-03 |
EP2170391B1 (en) | 2017-01-18 |
AU2008265767A2 (en) | 2010-01-28 |
AU2008265767A1 (en) | 2008-12-24 |
AU2008265767B2 (en) | 2014-11-13 |
EP2170391A4 (en) | 2011-07-27 |
CA2692069A1 (en) | 2008-12-24 |
EP2170391A1 (en) | 2010-04-07 |
WO2008157590A1 (en) | 2008-12-24 |
CN105267974A (zh) | 2016-01-27 |
CN101754773A (zh) | 2010-06-23 |
US20160175430A1 (en) | 2016-06-23 |
CA2692069C (en) | 2016-10-18 |
JP5555623B2 (ja) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214129A1 (zh) | 用於綴合疫苗的經過修飾的多糖 | |
IL211180B (en) | Attached polyethylene glycol and docetaxel | |
EP2271359A4 (en) | CAMPTOTHECINBINDING REST CONJUGATES | |
IL216719A0 (en) | Pure-peg-lipid conjugates | |
HK1138853A1 (en) | Vaccine | |
IL201782A0 (en) | Vaccine | |
GB0717911D0 (en) | Vaccine | |
IL208660A0 (en) | Coccididosis vaccines | |
ZA201001029B (en) | Vaccines | |
GB0700135D0 (en) | Vaccine | |
IL219735A0 (en) | Conjugate molecule | |
ZA201004303B (en) | Vaccine | |
GB0711858D0 (en) | Vaccine | |
GB0710538D0 (en) | Vaccine | |
ZA201003851B (en) | Vaccine | |
IL199718A0 (en) | Peptide-complement conjugates | |
GB0801326D0 (en) | Vaccines | |
EP2406304A4 (en) | ANTHRACYCLINE-LIPID CONJUGATES WITH GABA BINDING | |
GB0709373D0 (en) | BCG-based anti-atheroma vaccine | |
GB0906023D0 (en) | Insulin-Nanoparticle conjugates | |
GB0707697D0 (en) | Vaccine | |
GB0700760D0 (en) | Vaccine | |
GB0725107D0 (en) | Vaccine | |
GB0724651D0 (en) | Vaccine | |
GB0708522D0 (en) | Vaccine |